| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 23 | 2024 | 3016 | 1.360 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 377 | 0.650 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2024 | 1369 | 0.500 |
Why?
|
| Mastectomy | 4 | 2015 | 246 | 0.390 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 247 | 0.380 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2022 | 159 | 0.380 |
Why?
|
| Hyperparathyroidism | 3 | 2002 | 67 | 0.380 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 101 | 0.340 |
Why?
|
| Parathyroid Neoplasms | 2 | 2002 | 57 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 2568 | 0.300 |
Why?
|
| Adenoma | 2 | 2002 | 247 | 0.290 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 2023 | 0.270 |
Why?
|
| Aromatase Inhibitors | 1 | 2006 | 29 | 0.270 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 116 | 0.250 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 72 | 0.250 |
Why?
|
| Lymphadenopathy | 1 | 2024 | 20 | 0.230 |
Why?
|
| Middle Aged | 24 | 2024 | 26086 | 0.230 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 96 | 0.220 |
Why?
|
| Female | 33 | 2024 | 46391 | 0.220 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 81 | 0.210 |
Why?
|
| Mammaplasty | 3 | 2013 | 110 | 0.210 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2002 | 15 | 0.210 |
Why?
|
| Lymph Nodes | 2 | 2017 | 550 | 0.200 |
Why?
|
| Reoperation | 5 | 2013 | 603 | 0.200 |
Why?
|
| Parathyroidectomy | 1 | 2002 | 77 | 0.200 |
Why?
|
| Parathyroid Hormone | 1 | 2002 | 217 | 0.190 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 196 | 0.190 |
Why?
|
| Adenocarcinoma | 5 | 2003 | 1201 | 0.190 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 1720 | 0.180 |
Why?
|
| Intestinal Neoplasms | 1 | 2001 | 67 | 0.180 |
Why?
|
| Postoperative Complications | 4 | 2013 | 2286 | 0.170 |
Why?
|
| Adult | 20 | 2024 | 26708 | 0.170 |
Why?
|
| Body Weight | 1 | 2021 | 452 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2024 | 490 | 0.160 |
Why?
|
| Aged | 16 | 2024 | 19252 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 173 | 0.160 |
Why?
|
| Humans | 37 | 2024 | 89675 | 0.160 |
Why?
|
| Prognosis | 7 | 2024 | 3801 | 0.160 |
Why?
|
| Age Factors | 1 | 2023 | 1874 | 0.150 |
Why?
|
| Gastrinoma | 1 | 1996 | 2 | 0.140 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1996 | 10 | 0.140 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 204 | 0.140 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 36 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3461 | 0.130 |
Why?
|
| Radiotherapy | 3 | 2013 | 334 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2017 | 712 | 0.120 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6842 | 0.120 |
Why?
|
| Biopsy | 3 | 2018 | 1185 | 0.120 |
Why?
|
| Survival Rate | 4 | 2024 | 1909 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 417 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 972 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2001 | 763 | 0.120 |
Why?
|
| Phyllodes Tumor | 1 | 2013 | 7 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3671 | 0.110 |
Why?
|
| Mass Screening | 1 | 2018 | 641 | 0.110 |
Why?
|
| Esophageal Neoplasms | 4 | 2003 | 332 | 0.100 |
Why?
|
| Lymphokines | 3 | 2002 | 76 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2022 | 9091 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 181 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 539 | 0.100 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 55 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 687 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 856 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 785 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2019 | 479 | 0.090 |
Why?
|
| Breast | 2 | 2023 | 292 | 0.090 |
Why?
|
| Genetic Therapy | 2 | 2003 | 370 | 0.090 |
Why?
|
| Mammography | 3 | 2021 | 474 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2003 | 463 | 0.080 |
Why?
|
| Time Factors | 5 | 2013 | 5344 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2002 | 541 | 0.070 |
Why?
|
| Endothelium, Vascular | 4 | 2002 | 433 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2023 | 2879 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2021 | 4311 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 6 | 2005 | 1058 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2006 | 168 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 580 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2002 | 1280 | 0.060 |
Why?
|
| Glycine | 1 | 2005 | 95 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2005 | 302 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 170 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 699 | 0.060 |
Why?
|
| Radiation, Ionizing | 2 | 2000 | 123 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 277 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 296 | 0.050 |
Why?
|
| Mucin-1 | 1 | 2003 | 45 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2003 | 818 | 0.050 |
Why?
|
| Intraoperative Period | 1 | 2002 | 90 | 0.050 |
Why?
|
| Adolescent | 4 | 2015 | 9290 | 0.050 |
Why?
|
| Collagen | 2 | 2000 | 294 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 2415 | 0.050 |
Why?
|
| Young Adult | 3 | 2022 | 6350 | 0.050 |
Why?
|
| Body Weights and Measures | 1 | 2021 | 27 | 0.050 |
Why?
|
| Coumarins | 1 | 2000 | 13 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 165 | 0.050 |
Why?
|
| Neoplasm Transplantation | 4 | 2005 | 397 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 265 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 1099 | 0.040 |
Why?
|
| Male | 6 | 2016 | 42581 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 374 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1999 | 97 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 42 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 74 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 303 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 269 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 1999 | 232 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 774 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 340 | 0.040 |
Why?
|
| Mice | 8 | 2005 | 11807 | 0.040 |
Why?
|
| Axilla | 1 | 2017 | 104 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1535 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 951 | 0.040 |
Why?
|
| Anorexia | 1 | 1997 | 30 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 1999 | 364 | 0.040 |
Why?
|
| Transplantation, Heterologous | 3 | 2003 | 370 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 780 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 1997 | 171 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 1412 | 0.030 |
Why?
|
| Decision Trees | 1 | 1996 | 59 | 0.030 |
Why?
|
| Urinary Catheters | 1 | 2016 | 6 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 791 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1864 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1242 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1720 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 422 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 503 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1997 | 261 | 0.030 |
Why?
|
| Neoplasms | 2 | 2000 | 3080 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 783 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1996 | 184 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1997 | 389 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 606 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1997 | 259 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1996 | 395 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2002 | 1657 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1996 | 206 | 0.030 |
Why?
|
| Education, Medical | 1 | 2016 | 243 | 0.030 |
Why?
|
| Cytokines | 1 | 1997 | 805 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 4 | 2000 | 3229 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 1160 | 0.020 |
Why?
|
| Animals | 8 | 2005 | 27445 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2003 | 349 | 0.020 |
Why?
|
| Inflammation | 1 | 1997 | 972 | 0.020 |
Why?
|
| Genetic Vectors | 2 | 2003 | 446 | 0.020 |
Why?
|
| Umbilical Veins | 2 | 2000 | 46 | 0.020 |
Why?
|
| Carcinoma, Lewis Lung | 2 | 2000 | 24 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 56 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1990 | 49 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2000 | 2884 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 63 | 0.020 |
Why?
|
| Radiation Tolerance | 2 | 2002 | 173 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 315 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2354 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2003 | 961 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 264 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2002 | 424 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4165 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 1012 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 1944 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1601 | 0.020 |
Why?
|
| Escherichia coli | 2 | 2000 | 606 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2019 | 0.020 |
Why?
|
| Radiodermatitis | 1 | 2005 | 10 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 101 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 1092 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2005 | 371 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 307 | 0.010 |
Why?
|
| Apoptosis | 2 | 2002 | 1720 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2005 | 482 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5517 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 988 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 360 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 144 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 327 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2002 | 57 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1999 | 2020 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 309 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 155 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 276 | 0.010 |
Why?
|
| Virus Replication | 1 | 2003 | 326 | 0.010 |
Why?
|
| Isocoumarins | 1 | 2000 | 7 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 2000 | 4 | 0.010 |
Why?
|
| Endostatins | 1 | 2000 | 6 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 227 | 0.010 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 46 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 188 | 0.010 |
Why?
|
| Pichia | 1 | 2000 | 29 | 0.010 |
Why?
|
| Chicago | 1 | 2005 | 1432 | 0.010 |
Why?
|
| Laminin | 1 | 2000 | 89 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 203 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 123 | 0.010 |
Why?
|
| Microcirculation | 1 | 2000 | 104 | 0.010 |
Why?
|
| Cell Separation | 1 | 2000 | 199 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1999 | 37 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 646 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1999 | 88 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 983 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1999 | 103 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 691 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 1492 | 0.010 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 1997 | 1 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1997 | 4 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 785 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 42 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1999 | 265 | 0.010 |
Why?
|
| Leptin | 1 | 1997 | 102 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1997 | 130 | 0.010 |
Why?
|
| Interleukins | 1 | 1997 | 129 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1997 | 251 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1997 | 152 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1802 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 294 | 0.010 |
Why?
|
| Melanoma | 1 | 1999 | 470 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1144 | 0.010 |
Why?
|
| Kinetics | 1 | 1997 | 1534 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1997 | 512 | 0.010 |
Why?
|
| Proteins | 1 | 1997 | 787 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1990 | 32 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 3398 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 8276 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1999 | 2368 | 0.000 |
Why?
|
| Diabetes Mellitus | 1 | 1990 | 742 | 0.000 |
Why?
|